Genitourinary Drugs Market Report
RA01224
Genitourinary Drugs Market, by Indication (Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis, Hematuria, Benign Prostatic Hyperplasia), Product (Urologicals, Hormonal Therapy, Gynecological, Anti-infectives, Others): Global Opportunity Analysis and Industry Forecast, 2020-2027
The global genitourinary drugs market is estimated to surpass $42,495.9 million by 2027, exhibiting a CAGR of 3.0% from 2020 to 2027.
The report presents a comprehensive analysis of the global genitourinary drugs market by thoroughly examining several facets of the market including market drivers and restraints, key segments, major geographies, significant players, and competitive lookout.
The report portrays a detailed scenario of the current conditions and future scope of the global genitourinary drugs market based on various factors and events that impact market growth. The report highlights major drivers and opportunities which are contributing to the growth of the market. In addition, drawbacks and limitations that restrict the market growth are also deliberated in the report. The report also provides Porter’s five forces analysis which describes the factors affecting profitability of the global genitourinary drugs market.
The report furnishes market scope, size, and predictions by evaluating the major segments and sub-segments of the global genitourinary drugs market. Furthermore, the report highlights regional market scenario and scope of these segments by studying every market segment at regional and country level. The report classifies the global genitourinary drugs market into four main regions including Asia-Pacific, North America, Europe, and LAMEA. These regions are further sub-classified into countries to explain the country-level scenario and scope of the market.
In addition, the report provides competitive landscape of the global genitourinary drugs market. The foremost players functioning in the global genitourinary drugs market are premeditated in the report to comprehend their present position and dominance in the market. Moreover, the report provides various insights regarding these players such as company overview, company officials, financial status, key business strategies, novel initiatives and developments by the companies to withstand and upkeep their status in the global genitourinary drugs market.
Research Methodology
Our reports are formulated by expert, in-house market analysts by performing meticulous research and analysis on a variety of market facts, major events, and data-points including industry players’ interviews, consistent information from renowned sources, and regional insights. The market professionals have keen knowledge about various research methodologies, tools, and analysis. They use advanced analytical models and tools to filter the data and statistics and enhance the precision of the forecasts of the market.
This report has been articulated after long hours of deliberations, analysis, and interviews with several leading market stakeholders and players. A huge pile of product type literatures, annual reports, industry news, and other related pieces of information from significant industry participants have been studied for obtaining profound knowledge of the market. A combination of primary and secondary research has been applied for predicting the market statistics and forecasts. Secondary research methods focus on an extensive range of activities such as data mining of certified data sources including medical journals, trade association’s releases, independent studies, technical journals, and materials published by government and regulatory authorities.
KEY MARKET BENEFITS
- The report is a collation of meticulous market statistics and dynamics, data-points from market contributors and industry experts functioning in the industry, and quantitative and qualitative assessment by market analysts
- This report offers comprehensive breakdown of present market trends, governing factors, and macro-economic indicators from 2019 to 2027 to detect & comprehend the prevalent opportunities in the global genitourinary drugs market
- The report outlines the qualitative authority of numerous aspects on market segments as well as regions
- The market forecasts and future scope offered in the report are derived after complete analysis of latest & innovative advances in the genitourinary drugs market
- The growth and development strategies adopted by the prominent industry players are enlisted in the report to understand the competitive scenario of the genitourinary drugs market
KEY MARKET SEGMENTS
The global genitourinary drugs market is segmented based on the following:
- Indication: Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis, Hematuria, Benign Prostatic Hyperplasia
- Product: Urologicals, Hormonal Therapy, Gynecological, Anti-infectives, Others
This segment is further sub-segmented into the following regions:
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Argentina
- Saudi Arabia
- South Africa
- UAE
- Rest of LAMEA
KEY MARKET PLAYERS
The global genitourinary drugs market is highly competitive due to the existence of several major players in the industry. These players have brought in innovative and advanced products/services to obtain a foremost position in the market. The report outlines numerous factors of top ten key players such as recent strategic moves & developments, financial performance, product portfolio, and SWOT analysis.
Key players in the global genitourinary drugs market are as follows:
1. Abbott
2. Bristol-Myers Squibb Co.
3. Novartis AG
4. Genentech, Inc.
5. F. Hoffmann-La Roche Ltd
6. Ionis Pharmaceuticals, Inc.
7. Eli Lilly and Company
8. Merck & Co., Inc.
9. Pfizer, Inc.
10. AstraZeneca
11. GlaxoSmithKline
12. Teva Pharmaceutical Industries Ltd.
13. Bayer AG
14. Allergan
15. Antares Pharma
-
1. RESEARCH METHODOLOGY
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation
1.5.1. Top-down approach
1.5.2. Bottom-up approach
-
2. REPORT SCOPE
2.1. Market definition
2.2. Key objectives of the study
2.3. Report overview
2.4. Market segmentation
2.5. Overview of the impact of COVID-19 on Global Genitourinary Drugs Market
-
3. EXECUTIVE SUMMARY
-
4. MARKET OVERVIEW
4.1. Introduction
4.2. Growth impact forces
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Market value chain analysis
4.3.1. List of raw material suppliers
4.3.2. List of manufacturers
4.3.3. List of distributors
4.4. Innovation & sustainability matrices
4.4.1. Technology matrix
4.4.2. Regulatory matrix
4.5. Porter’s five forces analysis
4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive rivalry intensity
4.6. PESTLE analysis
4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Environmental
4.7. Impact of COVID-19 on Genitourinary Drugs Market
4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario
-
5. Genitourinary Drugs Market, By Disease Type
5.1. Overview
5.2 Prostate Cancer
5.2.1 Definition, key trends, growth factors, and opportunities
5.2.2 Market size analysis, by region, 2020-2027
5.2.3 Market share analysis, by country, 2020-2027
5.3 Ovarian Cancer
5.3.1 Definition, key trends, growth factors, and opportunities
5.3.2 Market size analysis, by region, 2020-2027
5.3.3 Market share analysis, by country, 2020-2027
5.4 Bladder Cancer
5.4.1 Definition, key trends, growth factors, and opportunities
5.4.2 Market size analysis, by region, 2020-2027
5.4.3 Market share analysis, by country, 2020-2027
5.5 Cervical Cancer
5.5.1 Definition, key trends, growth factors, and opportunities
5.5.2 Market size analysis, by region, 2020-2027
5.5.3 Market share analysis, by country, 2020-2027
5.6 Renal Cancer
5.6.1 Definition, key trends, growth factors, and opportunities
5.6.2 Market size analysis, by region, 2020-2027
5.6.3 Market share analysis, by country, 2020-2027
5.7 Erectile Dysfunction
5.7.1 Definition, key trends, growth factors, and opportunities
5.7.2 Market size analysis, by region, 2020-2027
5.7.3 Market share analysis, by country, 2020-2027
5.8 Urinary Tract Infections
5.8.1 Definition, key trends, growth factors, and opportunities
5.8.2 Market size analysis, by region, 2020-2027
5.8.3 Market share analysis, by country, 2020-2027
5.9 Urinary Incontinence & Overactive Bladder
5.9.1 Definition, key trends, growth factors, and opportunities
5.9.2 Market size analysis, by region, 2020-2027
5.9.3 Market share analysis, by country, 2020-2027
5.10 Sexually Transmitted Diseases
5.10.1 Definition, key trends, growth factors, and opportunities
5.10.2 Market size analysis, by region, 2020-2027
5.10.3 Market share analysis, by country, 2020-2027
5.11 Interstitial Cystitis
5.11.1 Definition, key trends, growth factors, and opportunities
5.11.2 Market size analysis, by region, 2020-2027
5.11.3 Market share analysis, by country, 2020-2027
5.12 Hematuria
5.12.1 Definition, key trends, growth factors, and opportunities
5.12.2 Market size analysis, by region, 2020-2027
5.12.3 Market share analysis, by country, 2020-2027
5.13 Benign Prostatic Hyperplasia
5.13.1 Definition, key trends, growth factors, and opportunities
5.13.2 Market size analysis, by region, 2020-2027
5.13.3 Market share analysis, by country, 2020-2027
5.14 Research Dive Exclusive Insights
5.14.1 Market attractiveness
5.14.2 Competition heatmap
-
6. Genitourinary Drugs Market, By Sector
6.1. Overview
6.2 Urologicals
6.2.1 Definition, key trends, growth factors, and opportunities
6.2.2 Market size analysis, by region, 2020-2027
6.2.3 Market share analysis, by country, 2020-2027
6.3 Hormonal Therapy
6.3.1 Definition, key trends, growth factors, and opportunities
6.3.2 Market size analysis, by region, 2020-2027
6.3.3 Market share analysis, by country, 2020-2027
6.4 Gynecological
6.4.1 Definition, key trends, growth factors, and opportunities
6.4.2 Market size analysis, by region, 2020-2027
6.4.3 Market share analysis, by country, 2020-2027
6.5 Anti-infectives
6.5.1 Definition, key trends, growth factors, and opportunities
6.5.2 Market size analysis, by region, 2020-2027
6.5.3 Market share analysis, by country, 2020-2027
6.6 Others
6.6.1 Definition, key trends, growth factors, and opportunities
6.6.2 Market size analysis, by region, 2020-2027
6.6.3 Market share analysis, by country, 2020-2027
6.7 Research Dive Exclusive Insights
6.7.1 Market attractiveness
6.7.2 Competition heatmap
7. Genitourinary Drugs Market, By Region
7.1 North America
7.1.1 U.S
7.1.1.1 Market size analysis, By Disease Type, 2020-2027
7.1.1.2 Market size analysis, By Sector, 2020-2027
7.1.2 Canada
7.1.2.1 Market size analysis, By Disease Type, 2020-2027
7.1.2.2 Market size analysis, By Sector, 2020-2027
7.1.3 Mexico
7.1.3.1 Market size analysis, By Disease Type, 2020-2027
7.1.3.2 Market size analysis, By Sector, 2020-2027
7.1.4 Research Dive Exclusive Insights
7.1.4.1 Market attractiveness
7.1.4.2 Competition heatmap
7.2 Europe
7.2.1 Germany
7.2.1.1 Market size analysis, By Disease Type, 2020-2027
7.2.1.2 Market size analysis, By Sector, 2020-2027
7.2.2 UK
7.2.2.1 Market size analysis, By Disease Type, 2020-2027
7.2.2.2 Market size analysis, By Sector, 2020-2027
7.2.3 France
7.2.3.1 Market size analysis, By Disease Type, 2020-2027
7.2.3.2 Market size analysis, By Sector, 2020-2027
7.2.4 Spain
7.2.4.1 Market size analysis, By Disease Type, 2020-2027
7.2.4.2 Market size analysis, By Sector, 2020-2027
7.2.5 Italy
7.2.5.1 Market size analysis, By Disease Type, 2020-2027
7.2.5.2 Market size analysis, By Sector, 2020-2027
7.2.6 Rest of Europe
7.2.6.1 Market size analysis, By Disease Type, 2020-2027
7.2.6.2 Market size analysis, By Sector, 2020-2027
7.2.7 Research Dive Exclusive Insights
7.2.7.1 Market attractiveness
7.2.7.2 Competition heatmap
7.3 Asia-Pacific
7.3.1 China
7.3.1.1 Market size analysis, By Disease Type, 2020-2027
7.3.1.2 Market size analysis, By Sector, 2020-2027
7.3.2 Japan
7.3.2.1 Market size analysis, By Disease Type, 2020-2027
7.3.2.2 Market size analysis, By Sector, 2020-2027
7.3.3 India
7.3.3.1 Market size analysis, By Disease Type, 2020-2027
7.3.3.2 Market size analysis, By Sector, 2020-2027
7.3.4 Australia
7.3.4.1 Market size analysis, By Disease Type, 2020-2027
7.3.4.2 Market size analysis, By Sector, 2020-2027
7.3.5 South Korea
7.3.5.1 Market size analysis, By Disease Type, 2020-2027
7.3.5.2 Market size analysis, By Sector, 2020-2027
7.3.6 Rest of Asia-Pacific
7.3.6.1 Market size analysis, By Disease Type, 2020-2027
7.3.6.2 Market size analysis, By Sector, 2020-2027
7.3.7 Research Dive Exclusive Insights
7.3.7.1 Market attractiveness
7.3.7.2 Competition heatmap
7.4 LAMEA
7.4.1 Brazil
7.4.1.1 Market size analysis, By Disease Type, 2020-2027
7.4.1.2 Market size analysis, By Sector, 2020-2027
7.4.2 Saudi Arabia
7.4.2.1 Market size analysis, By Disease Type, 2020-2027
7.4.2.2 Market size analysis, By Sector, 2020-2027
7.4.3 UAE
7.4.3.1 Market size analysis, By Disease Type, 2020-2027
7.4.3.2 Market size analysis, By Sector, 2020-2027
7.4.4 South Africa
7.4.4.1 Market size analysis, By Disease Type, 2020-2027
7.4.4.2 Market size analysis, By Sector, 2020-2027
7.4.5 Rest of LAMEA
7.4.5.1 Market size analysis, By Disease Type, 2020-2027
7.4.5.2 Market size analysis, By Sector, 2020-2027
7.4.6 Research Dive Exclusive Insights
7.4.6.1 Market attractiveness
7.4.6.2 Competition heatmap
8. Competitive Landscape
8.1 Top winning strategies, 2020-2027
8.1.1 By strategy
8.1.2 By year
8.2 Strategic overview
8.3 Market share analysis, 2020-2027
9. Company Profiles
9.1 Abbott
9.1.1 Overview
9.1.2 Business segments
9.1.3 Product portfolio
9.1.4 Financial performance
9.1.5 Recent developments
9.1.6 SWOT analysis
9.2 Bristol-Myers Squibb Co.
9.2.1 Overview
9.2.2 Business segments
9.2.3 Product portfolio
9.2.4 Financial performance
9.2.5 Recent developments
9.2.6 SWOT analysis
9.3 Novartis AG
9.3.1 Overview
9.3.2 Business segments
9.3.3 Product portfolio
9.3.4 Financial performance
9.3.5 Recent developments
9.3.6 SWOT analysis
9.4 Genentech, Inc.
9.4.1 Overview
9.4.2 Business segments
9.4.3 Product portfolio
9.4.4 Financial performance
9.4.5 Recent developments
9.4.6 SWOT analysis
9.5 F. Hoffmann-La Roche Ltd
9.5.1 Overview
9.5.2 Business segments
9.5.3 Product portfolio
9.5.4 Financial performance
9.5.5 Recent developments
9.5.6 SWOT analysis
9.6 Ionis Pharmaceuticals, Inc.
9.6.1 Overview
9.6.2 Business segments
9.6.3 Product portfolio
9.6.4 Financial performance
9.6.5 Recent developments
9.6.6 SWOT analysis
9.7 Eli Lilly and Company
9.7.1 Overview
9.7.2 Business segments
9.7.3 Product portfolio
9.7.4 Financial performance
9.7.5 Recent developments
9.7.6 SWOT analysis
9.8 Merck & Co., Inc.
9.8.1 Overview
9.8.2 Business segments
9.8.3 Product portfolio
9.8.4 Financial performance
9.8.5 Recent developments
9.8.6 SWOT analysis
9.9 Pfizer, Inc.
9.9.1 Overview
9.9.2 Business segments
9.9.3 Product portfolio
9.9.4 Financial performance
9.9.5 Recent developments
9.9.6 SWOT analysis
9.10 AstraZeneca
9.10.1 Overview
9.10.2 Business segments
9.10.3 Product portfolio
9.10.4 Financial performance
9.10.5 Recent developments
9.10.6 SWOT analysis
9.11 GlaxoSmithKline
9.11.1 Overview
9.11.2 Business segments
9.11.3 Product portfolio
9.11.4 Financial performance
9.11.5 Recent developments
9.11.6 SWOT analysis
9.12 Teva Pharmaceutical Industries Ltd.
9.12.1 Overview
9.12.2 Business segments
9.12.3 Product portfolio
9.12.4 Financial performance
9.12.5 Recent developments
9.12.6 SWOT analysis
9.13 Bayer AG
9.13.1 Overview
9.13.2 Business segments
9.13.3 Product portfolio
9.13.4 Financial performance
9.13.5 Recent developments
9.13.6 SWOT analysis
9.14 Allergan
9.14.1 Overview
9.14.2 Business segments
9.14.3 Product portfolio
9.14.4 Financial performance
9.14.5 Recent developments
9.14.6 SWOT analysis
9.15 Antares Pharma
9.15.1 Overview
9.15.2 Business segments
9.15.3 Product portfolio
9.15.4 Financial performance
9.15.5 Recent developments
9.15.6 SWOT analysis
Personalize this research
- Triangulate with your own data
- Request your format and definition
- Get a deeper dive on a specific application, geography, customer or competitor
- + 1-888-961-4454 Toll - Free
- support@researchdive.com
